Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-223-P01
Portuguese language
Published by: Harvard Business Publishing
Originally published in: 2022
Version: 7 November 2006
Length: 16 pages
Data source: Published sources

Abstract

This is a Portuguese version. Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC built a large short position in the stock. The defendants must consider specific and general strategic responses to these allegations.
Location:
Size:
USD1 billion revenues; 1,700 employees
Other setting(s):
2006

About

Abstract

This is a Portuguese version. Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC built a large short position in the stock. The defendants must consider specific and general strategic responses to these allegations.

Settings

Location:
Size:
USD1 billion revenues; 1,700 employees
Other setting(s):
2006

Related